Safety of everolimus plus exemestane in patients with hormone-receptor–positive, HER2–negative locally advanced or metastatic breast cancer progressing on prior non-steroidal aromatase inhibitors: primary results of a phase IIIb, open-label, single-arm, expanded-access multicenter trial (BALLET)

Publication | Open Access

DOI Full Paper Access

Citations

References

2016

Year

Guy Jérusalem, Gabriella Mariani, Eva Ciruelos, Miguel Martín, Vivianne C. G. Tjan‐Heijnen, P. Neven, J.G. Gavila, Andrea Michelotti, Filippo Montemurro, Daniele Generali,

Annals of Oncology

Endocrine OncologyMetastatic Breast CancerBreast OncologyEndocrine-related CancerMedicineExpanded-access Multicenter TrialPharmacologyClinical TrialsAromatasePharmacotherapyBreast CancerAnti-cancer AgentCancer TreatmentOncologyRadiation OncologyCancer ResearchPhase IiibHealth Sciences